Skip to main content

Table 1 Regimen and pumor assessment in patients enrolled in the RECORD-1 Phase 3 Trial

From: Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial

Patient category Total Everolimus arm Placebo arm
All 416 277 139
With baseline tumor measurement 407 272 135
Crossed over from placebo to everolimus 111 NA 111
Received at least one 5-mg dose of everolimus 98 69 29
Received at least one 5-mg dose and a subsequent tumor size assessment 68 53 15
  1. NA, not applicable.